Over the past two-and-one-half years, ArQule's new management has refocused the once divided company, and repaired its reputation in the eyes of the financial community. That leadership also decided that ArQule can reach its growth potential only by moving away from a fee-for-services model and becoming a full-fledged drug discovery company. It's a transition that few companies have successfully managed, in part because of the tough balancing act required to build the requisite R&D infrastructure, while devoting sufficient resources to the near-term activity needed to build that infrastructure. ArQule will likely try to acquire biology-based companies to gain control over its own targets, but must deal with the valuation imbalance that still favors genomics/biology firms. But ArQule's management believes that its technology platform--as enhanced by the addition of predictive ADMET modeling--will boost its ability to process target into targets and thus its value.
By Jeffrey Dvorin
When Stephen Hill, MD took the reins as president and CEO of ArQule Inc. in April 1999, he faced...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.